PCOS - PMOS
Is Polycystic Ovary Syndrome changing its name and philosophy?
For decades, the conversation surrounding Polycystic Ovary Syndrome (PCOS) revolved almost exclusively around gynecology and reproduction: irregular cycles, fertility issues, elevated androgens, and the classic ultrasound appearance of the ovaries.
Today, however, science is taking a major step forward. We now clearly understand that this is not merely a localized gynecological condition, but a complex, multisystem disorder deeply rooted in our endocrine and metabolic systems. For this reason, a new and far more precise term has been proposed internationally: Polyendocrine Metabolic Ovarian Syndrome (PMOS).
Why is this change not merely a "play on words"?
This renaming fundamentally shifts the clinical focus. We move beyond merely looking at the appearance of the ovary and instead focus on the biology of the entire organism.
At the heart of PMOS lies insulin resistance. This mechanism triggers a domino effect, influencing everything from androgen metabolism to proper follicular development. However, the syndrome is characterized by immense heterogeneity: metabolic dysfunction does not manifest in the same way or with the same intensity in every woman.
The major pitfall: A normal weight does not rule out the risk.
An important clinical truth, often misunderstood, lies here: the risk of glucose abnormalities and type 2 diabetes is elevated in women with PMOS, regardless of Body Mass Index (BMI).
Normal weight does not guarantee metabolic health. A patient’s assessment should never be limited to her outward appearance.
What the guidelines say: International guidelines (which now incorporate the new PMOS/PCOS terminology) recommend screening for glycemic status in all women with the syndrome.
The key test: The glucose tolerance test (75g OGTT) remains the most accurate diagnostic method.
What to avoid: Contrary to popular belief, simple fasting insulin measurements are not considered sufficiently reliable, and it is best not to use them as a routine test for diagnosing insulin resistance.
A holistic approach to Reproductive Endocrinology
From the point of view of endocrinology, this new perspective is a game-changer. We can no longer isolate reproductive symptoms (such as ovulation disorder) from the woman’s metabolic environment. Insulin, androgens, steroidogenesis and ovaries interact in a “closed”, complex network. This is why the syndrome manifests itself simultaneously on two boards: the reproductive and the metabolic.
The conclusion
The transition from PCOS to PMOS marks a profound shift in healthcare philosophy. The challenge for the modern clinician is no longer just to identify “polycystic ovaries” on an ultrasound. The essential challenge is to “read” the unique phenotype of each woman and design a personalized strategy that will shield both her reproductive and metabolic health over time.